Ardsley Advisory Partners’s Altimmune ALT Stock Holding History

Ardsley Advisory Partners’s Portfolio ALT Stock Details ALT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-250,000	Closed	-$1.66M	–	130
2024 Q2	$1.66M	Sell	250,000 -25,000	-9%	-$184K	0.24%	81
2024 Q1	$2.8M	Sell	275,000 -66,000	-19%	-$671K	0.4%	64
2023 Q4	$3.82M	Sell	341,000 -651,050	-66%	-$2.72M	0.59%	44
2023 Q3	$2.58M	Sell	992,050 -50,000	-5%	-$143K	0.58%	51
2023 Q2	$3.68M	Sell	1,042,050 -405,200	-28%	-$1.82M	0.62%	47
2023 Q1	$6.11M	Buy	1,447,250 +742,500	+105%	+$8.82M	1.34%	27
2022 Q4	$11.6M	Sell	704,750 -223,200	-24%	-$2.51M	2.4%	11
2022 Q3	$11.8M	Sell	927,950 -411,050	-31%	-$6.07M	2.65%	10
2022 Q2	$15.7M	Sell	1,339,000 -14,000	-1%	-$86.3K	2.58%	9
2022 Q1	$8.24M	Buy	1,353,000 +299,000	+28%	+$2.2M	1.37%	25
2021 Q4	$9.65M	Buy	1,054,000 +26,500	+3%	+$282K	1.84%	20
2021 Q3	$11.7M	Buy	1,027,500 +726,000	+241%	+$8.83M	1.79%	16
2021 Q2	$2.98M	Buy	+301,500	New	+$4.12M	0.35%	55

Other funds holding ALT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

KCM

Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Ardsley Advisory Partners's ALT Position: Q3 2024 in Review

Ardsley Advisory Partners sold out of Altimmune (ALT) in Q3 2024, closing a stake of 250,000 shares — an estimated $1.66M sold.

Ardsley Advisory Partners first reported a position in ALT in Q2 2021 and held it in 13 quarters. The position peaked at $15.7M in Q2 2022. 169 funds tracked by Wall St. Rank hold ALT as of Q3 2024.

Ardsley Advisory Partners reported no remaining Altimmune position as of Q3 2024 after selling out during the quarter.
Ardsley Advisory Partners sold 250,000 Altimmune shares in Q3 2024, an estimated $1.66M.
Ardsley Advisory Partners first reported a position in Altimmune in Q2 2021 and held it in 13 quarters.
Ardsley Advisory Partners's Altimmune position peaked at $15.7M in Q2 2022.
169 funds tracked by Wall St. Rank held Altimmune as of Q3 2024.

Based on Ardsley Advisory Partners's 13F filing for Q3 2024, filed 14 Nov 2024.